In our study, we found that SFRP2 methylation in whole blood is a potential biomarker for several cancer outcomes, while SFRP2 methylation in tumor tissue is a promising predictor for therapy response, suggesting its potential use in clinical practice. Here, SFRP2 is linked to neoplasm.